{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:10:06Z","timestamp":1792703406534,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Research Program of Chongqing Municipal Education Commission","award":["KJQN202200415"],"award-info":[{"award-number":["KJQN202200415"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03426-x","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:35:11Z","timestamp":1758875711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody-drug conjugates in triple-negative breast cancer (2010\u20132024): a bibliometric analysis of global trends and clinical translation"],"prefix":"10.1007","volume":"16","author":[{"given":"Xin-Yu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Lu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Dong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"3","key":"3426_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3426_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.22836","volume":"110","author":"GJ Morris","year":"2007","unstructured":"Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National cancer institute\u2019s surveillance, epidemiology, and end results database. Cancer. 2007;110(4):876\u201384.","journal-title":"Cancer"},{"issue":"22","key":"3426_CR3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im S-A, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in advanced Triple-Negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"issue":"1","key":"3426_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3426_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15(1):143. https:\/\/doi.org\/10.1186\/s13045-022-01362-9.","journal-title":"J Hematol Oncol"},{"key":"3426_CR6","doi-asserted-by":"publisher","unstructured":"Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers. 2020;12(6). https:\/\/doi.org\/10.3390\/cancers12061404.","DOI":"10.3390\/cancers12061404"},{"key":"3426_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","volume":"54","author":"H Kumar","year":"2023","unstructured":"Kumar H, Gupta NV, Jain R, Madhunapantula SV, Babu CS, Kesharwani SS, Dey S, Jain V. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res. 2023;54:271\u201392. https:\/\/doi.org\/10.1016\/j.jare.2023.02.005.","journal-title":"J Adv Res"},{"issue":"3","key":"3426_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"Y-F Chen","year":"2023","unstructured":"Chen Y-F, Xu Y-Y, Shao Z-M, Yu K-D. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023;43(3):297\u2013337. https:\/\/doi.org\/10.1002\/cac2.12387.","journal-title":"Cancer Commun (Lond)"},{"key":"3426_CR9","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.pharmthera.2022.108296","volume":"239","author":"X Liu","year":"2022","unstructured":"Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y, Huang H, Liang B, Ming T, Wen J, Huang B, Xing D. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108296.","journal-title":"Pharmacol Ther"},{"key":"3426_CR10","first-page":"3","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:3\u20134.","journal-title":"Genes Cancer"},{"issue":"5","key":"3426_CR11","doi-asserted-by":"publisher","first-page":"e96993","DOI":"10.1371\/journal.pone.0096993","volume":"9","author":"F Ambrogi","year":"2014","unstructured":"Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M, Piantelli M, Biganzoli E, Alberti S. Trop-2 is a determinant of breast cancer survival. PLoS ONE. 2014;9(5):e96993. https:\/\/doi.org\/10.1371\/journal.pone.0096993.","journal-title":"PLoS ONE"},{"issue":"26","key":"3426_CR12","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab Govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496\u2013512.","journal-title":"Oncotarget"},{"issue":"43","key":"3426_CR13","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.18632\/oncotarget.27766","volume":"11","author":"TM Cardillo","year":"2020","unstructured":"Cardillo TM, Rossi DL, Zalath MB, Liu D, Arrojo R, Sharkey RM, Chang C-H, Goldenberg DM. Predictive biomarkers for sacituzumab Govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget. 2020;11(43):3849\u201362. https:\/\/doi.org\/10.18632\/oncotarget.27766.","journal-title":"Oncotarget"},{"key":"3426_CR14","doi-asserted-by":"publisher","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga J-Y, Im S-A, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim S-B, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1). https:\/\/doi.org\/10.1056\/NEJMoa2203690.","DOI":"10.1056\/NEJMoa2203690"},{"issue":"9","key":"3426_CR15","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1097\/JS9.0000000000000492","volume":"109","author":"S Jiang","year":"2023","unstructured":"Jiang S, Liu Y, Zheng H, Zhang L, Zhao H, Sang X, Xu Y, Lu X. Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. Int J Surg. 2023;109(9):2774\u201383. https:\/\/doi.org\/10.1097\/JS9.0000000000000492.","journal-title":"Int J Surg"},{"key":"3426_CR16","doi-asserted-by":"publisher","first-page":"999312","DOI":"10.3389\/fmed.2023.999312","volume":"10","author":"K Wang","year":"2023","unstructured":"Wang K, Zheng C, Xue L, Deng D, Zeng L, Li M, Deng X. A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: progress in the past 17 years. Front Med. 2023;10:999312. https:\/\/doi.org\/10.3389\/fmed.2023.999312.","journal-title":"Front Med"},{"key":"3426_CR17","doi-asserted-by":"publisher","first-page":"1423924","DOI":"10.3389\/fonc.2024.1423924","volume":"14","author":"Q Xu","year":"2024","unstructured":"Xu Q, Feng X, Qin S, Hong Y, Cui R, Liang J, Xiao Z, Li Y. Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis. Front Oncol. 2024;14:1423924. https:\/\/doi.org\/10.3389\/fonc.2024.1423924.","journal-title":"Front Oncol"},{"issue":"2","key":"3426_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/path.4280","volume":"232","author":"BD Lehmann","year":"2014","unstructured":"Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142\u201350. https:\/\/doi.org\/10.1002\/path.4280.","journal-title":"J Pathol"},{"key":"3426_CR19","doi-asserted-by":"publisher","unstructured":"Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu K-D, Liu Y-R, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo W-J, Zhao S, Gong Y, Ren Y-X, Zhao Y-X, Yang Y-S, Niu Z, Cao Z-G, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li D-Q, Wang P, Shi L, Huang W, Shao Z-M. Genomic and transcriptomic landscape of Triple-Negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3). https:\/\/doi.org\/10.1016\/j.ccell.2019.02.001.","DOI":"10.1016\/j.ccell.2019.02.001"},{"issue":"10087","key":"3426_CR20","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(16)32454-0.","journal-title":"Lancet"},{"key":"3426_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"F Borri","year":"2021","unstructured":"Borri F, Granaglia A. Pathology of triple negative breast cancer. Sem Cancer Biol. 2021;72:136\u201345. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.005.","journal-title":"Sem Cancer Biol"},{"issue":"8","key":"3426_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/djae056","volume":"116","author":"N Kumar","year":"2024","unstructured":"Kumar N, Ehsan S, Banerjee S, Fernandez Perez C, Lhuilier I, Neuner J, Friebel-Klingner T, Fayanju OM, Nair B, Niinuma SA, Nampoothiri S, McCarthy AM. The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis. J Natl Cancer Inst. 2024;116(8):1210\u20139. https:\/\/doi.org\/10.1093\/jnci\/djae056.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3426_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12935-024-03261-0","volume":"24","author":"L Weng","year":"2024","unstructured":"Weng L, Zhou J, Guo S, Xu N, Ma R. The molecular subtyping and precision medicine in triple-negative breast cancer\u2014based on Fudan TNBC classification. Cancer Cell Int. 2024;24(1):120. https:\/\/doi.org\/10.1186\/s12935-024-03261-0.","journal-title":"Cancer Cell Int"},{"key":"3426_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast (Edinburgh Scotland). 2022;66:169\u201377. https:\/\/doi.org\/10.1016\/j.breast.2022.10.007.","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"19","key":"3426_CR25","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O\u2019Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and safety of Anti-Trop-2 antibody drug conjugate sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic Triple-Negative breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35(19):2141\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.70.8297.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"3426_CR26","doi-asserted-by":"publisher","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24(11). https:\/\/doi.org\/10.3390\/ijms24119674.","DOI":"10.3390\/ijms24119674"},{"issue":"18","key":"3426_CR27","doi-asserted-by":"publisher","first-page":"16296","DOI":"10.1021\/acsami.9b02016","volume":"11","author":"Y Gao","year":"2019","unstructured":"Gao Y, Jia L, Wang Q, Hu H, Zhao X, Chen D, Qiao M. pH\/Redox Dual-Responsive polyplex with effective endosomal escape for codelivery of SiRNA and doxorubicin against Drug-Resistant cancer cells. ACS Appl Mater Interfaces. 2019;11(18):16296\u2013310. https:\/\/doi.org\/10.1021\/acsami.9b02016.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3426_CR28","doi-asserted-by":"publisher","unstructured":"Rischin D, Hughes BGM, Basset-S\u00e9guin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dr\u00e9no B, Migden MR, Hauschild A, Schmults CD, Lim AM, Yoo S-Y, Paccaly AJ, Papachristos A, Nguyen J-H, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A. High response rate with extended dosing of Cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2024;12(3). https:\/\/doi.org\/10.1136\/jitc-2023-008325.","DOI":"10.1136\/jitc-2023-008325"},{"issue":"4","key":"3426_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.annonc.2024.12.010","volume":"36","author":"A Fernandez-Martinez","year":"2025","unstructured":"Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, Pascual T, Rediti M, Tang G, Hoadley KA, Venet D, Rashid NU, Spears PA, Di Cosimo S, de Azambuja E, Choudhury A, Rastogi P, Islam MN, Cortes J, Llombart-Cussac A, Swain SM, Sotiriou C, Prat A, Perou CM, Carey LA. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). Annals Oncology: Official J Eur Soc Med Oncol. 2025;36(4):403\u201313. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.010.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"1","key":"3426_CR30","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1038\/s41467-023-40715-x","volume":"14","author":"L-J Dai","year":"2023","unstructured":"Dai L-J, Ma D, Xu Y-Z, Li M, Li Y-W, Xiao Y, Jin X, Wu S-Y, Zhao Y-X, Wang H, Yang W-T, Jiang Y-Z, Shao Z-M. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nat Commun. 2023;14(1):5112. https:\/\/doi.org\/10.1038\/s41467-023-40715-x.","journal-title":"Nat Commun"},{"issue":"5","key":"3426_CR31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12282-024-01597-z","volume":"31","author":"P J\u00e9z\u00e9quel","year":"2024","unstructured":"J\u00e9z\u00e9quel P, Lasla H, Gouraud W, Basseville A, Michel B, Frenel J-S, Juin PP, Ben Azzouz F, Campone M. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype. Breast Cancer (Tokyo Japan). 2024;31(5):825\u201340. https:\/\/doi.org\/10.1007\/s12282-024-01597-z.","journal-title":"Breast Cancer (Tokyo Japan)"},{"issue":"5","key":"3426_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamaoncol.2023.7304","volume":"10","author":"A Fernandez-Martinez","year":"2024","unstructured":"Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA. Tumor intrinsic subtypes and gene expression signatures in Early-Stage ERBB2\/HER2-Positive breast cancer: A pooled analysis of CALGB 40601, neoaltto, and NSABP B-41 trials. JAMA Oncol. 2024;10(5):603\u201311. https:\/\/doi.org\/10.1001\/jamaoncol.2023.7304.","journal-title":"JAMA Oncol"},{"issue":"17","key":"3426_CR33","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","volume":"77","author":"C R\u00edos-Luci","year":"2017","unstructured":"R\u00edos-Luci C, Garc\u00eda-Alonso S, D\u00edaz-Rodr\u00edguez E, Nadal-Serrano M, Arribas J, Oca\u00f1a A, Pandiella A. Resistance to the Antibody-Drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017;77(17):4639\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3127.","journal-title":"Cancer Res"},{"issue":"4","key":"3426_CR34","doi-asserted-by":"publisher","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, Wang X, Lu H. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochim Et Biophys Acta Reviews Cancer. 2023;1878(4):188902. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188902.","journal-title":"Biochim Et Biophys Acta Reviews Cancer"},{"issue":"8","key":"3426_CR35","doi-asserted-by":"publisher","first-page":"e70011","DOI":"10.1002\/cbf.70011","volume":"42","author":"CL Li","year":"2024","unstructured":"Li CL, Ma XY, Yi P, Bispecific Antibodies. Immune checkpoint inhibitors, and Antibody-Drug conjugates directing antitumor immune responses: challenges and prospects. Cell Biochem Funct. 2024;42(8):e70011. https:\/\/doi.org\/10.1002\/cbf.70011.","journal-title":"Cell Biochem Funct"},{"issue":"10371","key":"3426_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning J-W, Curigliano G, Perez-Garcia JM, Kim S-B, Petry V, Huang C-S, Li W, Frenel J-S, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cort\u00e9s J. Trastuzumab Deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"Lancet"},{"issue":"5","key":"3426_CR37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti C, Giugliano F, Nicol\u00f2 E, Tarantino P, Criscitiello C, Curigliano G. HER2-Low breast cancer: a new subtype?? Curr Treat Options Oncol. 2023;24(5):468\u201378. https:\/\/doi.org\/10.1007\/s11864-023-01068-1.","journal-title":"Curr Treat Options Oncol"},{"key":"3426_CR38","doi-asserted-by":"publisher","unstructured":"Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician\u2019s choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025;30(5). https:\/\/doi.org\/10.1093\/oncolo\/oyaf048.","DOI":"10.1093\/oncolo\/oyaf048"},{"issue":"8","key":"3426_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"3426_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrclinonc.2017.123","volume":"14","author":"O Metzger-Filho","year":"2017","unstructured":"Metzger-Filho O, Winer EP. Breast cancer: T-DM1 - an important agent in the history of breast cancer management. Nat Reviews Clin Oncol. 2017;14(11):651\u20132. https:\/\/doi.org\/10.1038\/nrclinonc.2017.123.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"5","key":"3426_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1758834014539183","volume":"6","author":"PF Peddi","year":"2014","unstructured":"Peddi PF, Hurvitz SA. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Therapeutic Adv Med Oncol. 2014;6(5):202\u20139. https:\/\/doi.org\/10.1177\/1758834014539183.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"7","key":"3426_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, W\u00fclfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE. Trastuzumab emtansine for residual invasive HER2-Positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"issue":"1","key":"3426_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.critrevonc.2015.02.002","volume":"95","author":"G Mustacchi","year":"2015","unstructured":"Mustacchi G, Biganzoli L, Pronzato P, Montemurro F, Dambrosio M, Minelli M, Molteni L, Scaltriti L. HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol\/Hematol. 2015;95(1):78\u201387. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.02.002.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"8","key":"3426_CR44","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","volume":"32","author":"EP Mamounas","year":"2021","unstructured":"Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(8):1005\u201314. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.011.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"2","key":"3426_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2159-8290.CD-ND2022-0020","volume":"13","author":"T-DXd Keeps Shining in Breast Cancer","year":"2023","unstructured":"T-DXd Keeps Shining in Breast Cancer. Cancer Discov. 2023;13(2):254. https:\/\/doi.org\/10.1158\/2159-8290.CD-ND2022-0020.","journal-title":"Cancer Discov"},{"issue":"10","key":"3426_CR46","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.annonc.2023.07.003","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Tolaney SM, Curigliano G. Trastuzumab Deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Annals Oncology: Official J Eur Soc Med Oncol. 2023;34(10):949\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.003.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"10","key":"3426_CR47","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.annonc.2023.07.004","volume":"34","author":"T Wei","year":"2023","unstructured":"Wei T, Wang D, Yuan P. The role of trastuzumab Deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Annals Oncology: Official J Eur Soc Med Oncol. 2023;34(10):948\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.004.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"9","key":"3426_CR48","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, Xing D, Yan S, Zhang M. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024;14(9):3674\u201392. https:\/\/doi.org\/10.7150\/thno.98178.","journal-title":"Theranostics"},{"issue":"12","key":"3426_CR49","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O\u2019Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab Govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(12):1709\u201318. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.004.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"9","key":"3426_CR50","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O\u2019Shaughnessy J, Cortes J, Tsai M, Vahdat L, Di\u00e9ras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. Biomarker analyses in the phase III ASCENT study of sacituzumab Govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(9):1148\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"2","key":"3426_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-022-06602-7","volume":"195","author":"J O\u2019Shaughnessy","year":"2022","unstructured":"O\u2019Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cort\u00e9s J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab Govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022;195(2):127\u201339. https:\/\/doi.org\/10.1007\/s10549-022-06602-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"3426_CR52","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O\u2019Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(6):746\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"3","key":"3426_CR53","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1056\/NEJMc2108478","volume":"385","author":"S Ganguly","year":"2021","unstructured":"Ganguly S, Gogia A. Sacituzumab Govitecan in metastatic breast cancer. N Engl J Med. 2021;385(3):e12. https:\/\/doi.org\/10.1056\/NEJMc2108478.","journal-title":"N Engl J Med"},{"issue":"15","key":"3426_CR54","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cort\u00e9s J, Shaughnessy JO, Di\u00e9ras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan S-C, Hurvitz SA. Final results from the randomized phase III ASCENT clinical trial in metastatic Triple-Negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncology: Official J Am Soc Clin Oncol. 2024;42(15):1738\u201344. https:\/\/doi.org\/10.1200\/JCO.23.01409.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"3","key":"3426_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the Antibody-Drug conjugate, [fam-] trastuzumab Deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173\u201385. https:\/\/doi.org\/10.1248\/cpb.c18-00744.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"12","key":"3426_CR56","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T. Datopotamab deruxtecan, a novel TROP2-directed Antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20(12):2329\u201340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0206.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"3426_CR57","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F. Datopotamab Deruxtecan in advanced or metastatic HR+\/HER2- and Triple-Negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncology: Official J Am Soc Clin Oncol. 2024;42(19):2281\u201394. https:\/\/doi.org\/10.1200\/JCO.23.01909.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"35","key":"3426_CR58","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2217\/fon-2023-0228","volume":"19","author":"RA Dent","year":"2023","unstructured":"Dent RA, Cescon DW, Bachelot T, Jung KH, Shao Z-M, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cort\u00e9s J. TROPION-Breast02: Datopotamab Deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023;19(35):2349\u201359. https:\/\/doi.org\/10.2217\/fon-2023-0228.","journal-title":"Future Oncol"},{"issue":"16suppl","key":"3426_CR59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","volume":"42","author":"B Xu","year":"2024","unstructured":"Xu B, Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, Li M, Yan X, Wang S, Sun T, Teng Y, Tang X, Tong Z, Sun Z, Jin X, Diao Y, Liu G, Ge J. Sacituzumab Tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study. J Clin Oncol. 2024;42(16suppl):104. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.104.","journal-title":"J Clin Oncol"},{"key":"3426_CR60","doi-asserted-by":"publisher","first-page":"175883592091598","DOI":"10.1177\/1758835920915980","volume":"12","author":"A Nagayama","year":"2020","unstructured":"Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Therapeutic Adv Med Oncol. 2020;12:1758835920915980. https:\/\/doi.org\/10.1177\/1758835920915980.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"4","key":"3426_CR61","doi-asserted-by":"publisher","first-page":"e31203","DOI":"10.1002\/jcp.31203","volume":"239","author":"R Saravanan","year":"2024","unstructured":"Saravanan R, Balasubramanian V, Sundaram S, Dev B, Vittalraj P, Pitani RS, Shanmugasundaram G, Rayala SK, Venkatraman G. Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure. J Cell Physiol. 2024;239(4):e31203. https:\/\/doi.org\/10.1002\/jcp.31203.","journal-title":"J Cell Physiol"},{"issue":"11","key":"3426_CR62","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1002\/jcp.30880","volume":"237","author":"R Saravanan","year":"2022","unstructured":"Saravanan R, Balasubramanian V, Swaroop Balamurugan SS, Ezhil I, Afnaan Z, John J, Sundaram S, Gouthaman S, Pakala SB, Rayala SK, Venkatraman G. Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer. J Cell Physiol. 2022;237(11):4132\u201356. https:\/\/doi.org\/10.1002\/jcp.30880.","journal-title":"J Cell Physiol"},{"key":"3426_CR63","doi-asserted-by":"publisher","unstructured":"Han HS, Alemany CA, Brown-Glaberman UA, Pluard TJ, Sinha R, Sterrenberg D, Albain KS, Basho RK, Biggs D, Boni V, Diab S, Tsai ML, Tkaczuk KH, Wang Y, Wang Z, Meisel JL. SGNLVA-002: Single-arm, open label phase ib\/ii study of Ladiratuzumab Vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer. 2019;37(15_suppl):TPS1110\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS1110.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS1110"},{"issue":"4Supplement","key":"3426_CR64","doi-asserted-by":"publisher","first-page":"OT2","DOI":"10.1158\/1538-7445.SABCS18-OT2-06-04","volume":"79","author":"D Yardley","year":"2019","unstructured":"Yardley D, Abu-Khalaf M, Boni V, Brufsky A, Emens L, Gutierrez M, Hurvitz S, Im S-A, Loi S, McCune S, Schmid P, O\u2019Hear C, Zhang X, Vidal G. Abstract OT2-06-04: MORPHEUS: A phase ib\/ii trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor\u2013positive and triple-negative breast cancer. Cancer Res. 2019;79(4Supplement):OT2. https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-OT2-06-04. Cancer Research.","journal-title":"Cancer Res"},{"issue":"13Supplement","key":"3426_CR65","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1158\/1538-7445.AM2019-218","volume":"218","author":"MJ Thwaites","year":"2019","unstructured":"Thwaites MJ, Figueredo R, Tremblay G, Koropatnick J, Goldmacher V, O\u2019Connor-McCourt M, Abstract. AVID100 is an anti-EGFR ADC that promotes DM1-meditated cytotoxicity on cancer cells but not on normal cells. Cancer Res. 2019;218(13Supplement):218. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-218. Cancer Research.","journal-title":"Cancer Res"},{"issue":"4","key":"3426_CR66","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/annonc\/mdw678","volume":"28","author":"M M-Rabet","year":"2017","unstructured":"M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gon\u00e7alves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(4):769\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdw678.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"3426_CR67","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fmed.2019.00200","volume":"6","author":"J Zeindler","year":"2019","unstructured":"Zeindler J, Soysal SD, Piscuoglio S, Ng CKY, Mechera R, Isaak A, Weber WP, Muenst S, Kurzeder C. Nectin-4 expression is an independent prognostic biomarker and associated with better survival in Triple-Negative breast cancer. Front Med. 2019;6:200. https:\/\/doi.org\/10.3389\/fmed.2019.00200.","journal-title":"Front Med"},{"key":"3426_CR68","doi-asserted-by":"publisher","first-page":"1354543","DOI":"10.3389\/fonc.2024.1354543","volume":"14","author":"K Li","year":"2024","unstructured":"Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024;14:1354543. https:\/\/doi.org\/10.3389\/fonc.2024.1354543.","journal-title":"Front Oncol"},{"key":"3426_CR69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/cdr.2024.180","volume":"8","author":"\u00c9A Larose","year":"2025","unstructured":"Larose \u00c9A, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resist. 2025;8:11. https:\/\/doi.org\/10.20517\/cdr.2024.180.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"3426_CR70","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, Lam M-H, Hu W, Charati MB, Khandke K, Kim KSK, Cinque M, Lucas J, Graziani E, Maderna A, O\u2019Donnell CJ, Arndt KT, Gerber H-P. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952\u201363. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0862.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3426_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","volume":"65","author":"P Nagy","year":"2005","unstructured":"Nagy P, Friedl\u00e4nder E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65(2):473\u201382.","journal-title":"Cancer Res"},{"key":"3426_CR72","doi-asserted-by":"publisher","first-page":"102672","DOI":"10.1016\/j.ctrv.2023.102672","volume":"123","author":"A Dri","year":"2024","unstructured":"Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treat Rev. 2024;123:102672. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102672.","journal-title":"Cancer Treat Rev"},{"key":"3426_CR73","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-cellbio-092910-154152","volume":"28","author":"PI Hanson","year":"2012","unstructured":"Hanson PI, Cashikar A. Multivesicular body morphogenesis. Annu Rev Cell Dev Biol. 2012;28:337\u201362. https:\/\/doi.org\/10.1146\/annurev-cellbio-092910-154152.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"6","key":"3426_CR74","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/CCO.0000000000001087","volume":"36","author":"L Guidi","year":"2024","unstructured":"Guidi L, Boldrini L, Trapani D, Curigliano G. Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances. Curr Opin Oncol. 2024;36(6):487\u201394. https:\/\/doi.org\/10.1097\/CCO.0000000000001087.","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"3426_CR75","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","volume":"17","author":"G Li","year":"2018","unstructured":"Li G, Guo J, Shen B-Q, Yadav DB, Sliwkowski MX, Crocker LM, Lacap JA, Phillips GDL. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 2018;17(7):1441\u201353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0296.","journal-title":"Mol Cancer Ther"},{"issue":"10Supplement","key":"3426_CR76","doi-asserted-by":"publisher","first-page":"A059","DOI":"10.1158\/2326-6074.TUMIMM24-A059","volume":"12","author":"L-C Tsao","year":"2024","unstructured":"Tsao L-C, Wang JS, Ragusa J, Liu B, McBane J, Spasojevic I, Fan P, Trotter TN, Lyerly HK, Hartman ZC. Abstract A059: Uncovering bystander killing mechanisms of trastuzumab Deruxtecan (T-DXd): effective extracellular payload release via cathepsin L in HER2-low breast cancer. Cancer Immunol Res. 2024;12(10Supplement):A059\u2013A. https:\/\/doi.org\/10.1158\/2326-6074.TUMIMM24-A059. Cancer Immunology Research.","journal-title":"Cancer Immunol Res"},{"key":"3426_CR77","doi-asserted-by":"publisher","unstructured":"Najjar MK, Manore SG, Regua AT, Lo H-W. Antibody-Drug conjugates for the treatment of HER2-Positive breast cancer. Genes. 2022;13(11). https:\/\/doi.org\/10.3390\/genes13112065.","DOI":"10.3390\/genes13112065"},{"key":"3426_CR78","doi-asserted-by":"publisher","unstructured":"Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of resistance to Antibody-Drug conjugates. Cancers. 2023;15(4). https:\/\/doi.org\/10.3390\/cancers15041278.","DOI":"10.3390\/cancers15041278"},{"issue":"1","key":"3426_CR79","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1038\/s41598-024-57832-2","volume":"14","author":"M-R Kwon","year":"2024","unstructured":"Kwon M-R, Youn I, Ko ES, Choi S-H. Correlation of shear-wave elastography stiffness and apparent diffusion coefficient values with tumor characteristics in breast cancer. Sci Rep. 2024;14(1):7180. https:\/\/doi.org\/10.1038\/s41598-024-57832-2.","journal-title":"Sci Rep"},{"key":"3426_CR80","doi-asserted-by":"publisher","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Investig. 2023;133(18). https:\/\/doi.org\/10.1172\/JCI172156.","DOI":"10.1172\/JCI172156"},{"issue":"9","key":"3426_CR81","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","volume":"10","author":"P Zhao","year":"2020","unstructured":"Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sinica B. 2020;10(9):1589\u2013600. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.012.","journal-title":"Acta Pharm Sinica B"},{"issue":"5","key":"3426_CR82","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/jrsm.1729","volume":"15","author":"M Gusenbauer","year":"2024","unstructured":"Gusenbauer M. Beyond Google scholar, scopus, and web of science: an evaluation of the backward and forward citation coverage of 59 databases\u2019 citation indices. Res Synth Methods. 2024;15(5):802\u201317. https:\/\/doi.org\/10.1002\/jrsm.1729.","journal-title":"Res Synth Methods"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03426-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:35:15Z","timestamp":1758875715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03426-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3426"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03426-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was needed because this is not a human study, but only online information was used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1720"}}